BNT327

TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring homozygous MTAP deletion receive BMS-986504, an investigational MTA-cooperative PRMT5 inhibitor, alone or in tumor-specific combinations. Combination cohorts pair it with pumitamig (a PD-L1/VEGF-A bispecific antibody) and chemotherapy; daraxonrasib (a RAS(ON) inhibitor), with or without chemotherapy; nivolumab plus relatlimab; or temozolomide and radiotherapy.

ClinicalTrials.gov ID: NCT07492680

TrialFetch AI summary: Adults with untreated stage IV or recurrent unresectable NSCLC, ECOG 0–1, and no actionable alteration warranting approved first-line targeted therapy are randomized to pumitamig plus histology-directed platinum-doublet chemotherapy with or without imzokitug. Pumitamig targets PD-L1 and VEGF-A; imzokitug targets CCR8 to deplete tumor-infiltrating regulatory T cells.

ClinicalTrials.gov ID: NCT07680764

TrialFetch AI summary: Adults with measurable, unresectable locally advanced or metastatic RCC are eligible; Part 1 includes clear-cell and non-clear-cell disease and permits some previously treated patients, while Part 2 is limited to clear-cell disease. The study evaluates pumitamig, an investigational PD-L1/VEGF-A bispecific antibody, with ipilimumab or cabozantinib, with comparator arms of nivolumab plus ipilimumab or nivolumab alone.

ClinicalTrials.gov ID: NCT07293351

TrialFetch AI summary: For patients with locally advanced or unresectable HCC, ECOG 0–1, and no prior systemic therapy for advanced disease, this study evaluates first-line pumitamig alone or with ipilimumab against atezolizumab plus bevacizumab. Pumitamig is an investigational bispecific antibody targeting PD-L1 and VEGF-A; ipilimumab blocks CTLA-4.

ClinicalTrials.gov ID: NCT07291076

TrialFetch AI summary: For patients with previously untreated stage IIIB/IIIC or IV NSCLC, PD-L1 expression ≥50%, and ECOG performance status 0–1, this study compares first-line pumitamig monotherapy with pembrolizumab. Pumitamig is an investigational bispecific antibody targeting PD-L1 and VEGF-A; patients with actionable alterations warranting approved first-line therapy are excluded.

ClinicalTrials.gov ID: NCT07361510

TrialFetch AI summary: Adults with previously untreated, unresectable recurrent or metastatic colorectal adenocarcinoma are eligible, excluding those with known dMMR/MSI-H disease or a BRAF V600E mutation. The trial compares first-line chemotherapy (FOLFOX, FOLFIRI, or CAPOX) plus pumitamig, an investigational PD-L1/VEGF-A bispecific antibody, with the same chemotherapy plus bevacizumab.

ClinicalTrials.gov ID: NCT07221357

TrialFetch AI summary: For patients with previously untreated, inoperable locally recurrent or metastatic PD-L1–negative TNBC or ER-low (1%–10%), HER2-negative breast cancer who are ineligible for standard PD-(L)1 therapy, this trial compares physician’s-choice chemotherapy plus pumitamig with chemotherapy plus placebo. Pumitamig is an investigational bispecific antibody targeting PD-L1 and VEGF-A.

ClinicalTrials.gov ID: NCT07173751

TrialFetch AI summary: For adults with previously untreated, HER2-negative, PD-L1–positive (≥1) advanced or metastatic gastric, gastroesophageal junction, or distal esophageal adenocarcinoma, this trial compares pumitamig plus platinum-fluoropyrimidine chemotherapy with nivolumab plus the same chemotherapy. Pumitamig is an investigational bispecific antibody targeting PD-L1 and VEGF-A.

ClinicalTrials.gov ID: NCT07221149

TrialFetch AI summary: Adults with advanced or recurrent NSCLC and ECOG 0–1 are eligible for cohorts spanning previously treated disease, including EGFR-mutant disease after EGFR inhibitors, and untreated disease without actionable alterations. Treatment centers on BNT326, a HER3-directed antibody–drug conjugate delivering a topoisomerase-I inhibitor, plus BNT327, a PD-L1/VEGF-A bispecific antibody; selected cohorts also evaluate either drug alone or compare the combination with first-line pembrolizumab-based treatment.

ClinicalTrials.gov ID: NCT07111520

TrialFetch AI summary: Adults with measurable advanced or recurrent solid tumors, including previously treated melanoma, NSCLC, and HER2-negative breast cancer, receive BNT326 (beruzatatug pelitecan), a HER3-directed antibody–drug conjugate carrying a topoisomerase-I inhibitor. Melanoma and HER2-negative breast cancer cohorts also evaluate BNT326 with BNT327 (pumitamig), a PD-L1/VEGF-A bispecific antibody.

ClinicalTrials.gov ID: NCT07070232

TrialFetch AI summary: This trial enrolls patients with unresectable, measurable, non-MSI-H/pMMR metastatic colorectal cancer and ECOG 0–1; prior-treatment requirements vary by cohort, including a previously untreated cohort. It evaluates BNT314, an EpCAM×4-1BB bispecific antibody, with BNT327, a PD-L1×VEGF-A bispecific antibody, with or without chemotherapy; the randomized portion compares the combination plus chemotherapy against BNT327 plus chemotherapy and bevacizumab plus chemotherapy.

ClinicalTrials.gov ID: NCT07079631

TrialFetch AI summary: Adults with measurable recurrent or advanced/metastatic hepatocellular, cervical, melanoma, head and neck squamous, platinum-resistant high-grade serous ovarian, or non-small cell lung cancer and ECOG 0–1 receive DB-1311, a B7-H3–targeted topoisomerase I inhibitor antibody–drug conjugate. It is combined with either BNT327, a PD-L1/VEGF-A bispecific antibody, or DB-1305, a TROP2-targeted topoisomerase I inhibitor antibody–drug conjugate.

ClinicalTrials.gov ID: NCT06953089

TrialFetch AI summary: Adults with unresectable advanced or metastatic NSCLC or SCLC, including first-line and previously treated cohorts, receive BNT324 (DB-1311), a B7-H3–targeted antibody–drug conjugate carrying a topoisomerase I inhibitor, plus BNT327 (pumitamig), a PD-L1/VEGF-A bispecific antibody. The study evaluates combination dosing, safety, and preliminary antitumor activity without a standard-of-care comparator.

ClinicalTrials.gov ID: NCT06892548

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic breast cancer are eligible across HER2-positive, HER2-low, HER2-ultralow, HER2-null, and triple-negative cohorts; dose escalation is limited to chemotherapy-pretreated HR-positive, HER2-low or HER2-ultralow disease. Treatment combines BNT323, a HER2-directed antibody–drug conjugate delivering a topoisomerase I inhibitor, with BNT327, a PD-L1/VEGF-A bispecific antibody; a randomized cohort also evaluates each drug alone.

ClinicalTrials.gov ID: NCT06827236

TrialFetch AI summary: Adults with stage IV NSCLC that progressed after one platinum-based chemoimmunotherapy regimen receive docetaxel plus investigational BNT327 (pumitamig), a bispecific antibody targeting PD-L1 and VEGF-A. Eligible patients must have ECOG performance status 0–1 and no prior docetaxel or anti-VEGF antibody treatment.

ClinicalTrials.gov ID: NCT06841055

TrialFetch AI summary: Adults with previously untreated, measurable extensive-stage small-cell lung cancer and ECOG performance status 0–1 are randomized to pumitamig (BNT327), an investigational PD-L1/VEGF-A bispecific antibody, or the PD-L1 inhibitor atezolizumab, each with etoposide and platinum chemotherapy.

ClinicalTrials.gov ID: NCT06712355

TrialFetch AI summary: Adults with previously untreated, unresectable stage IIIB/IIIC or stage IV NSCLC without actionable EGFR mutations or ALK rearrangements receive histology-appropriate carboplatin/pemetrexed or carboplatin/paclitaxel plus either investigational pumitamig (BNT327), a PD-L1/VEGF-A bispecific antibody, or pembrolizumab.

ClinicalTrials.gov ID: NCT06712316